Contineum Therapeutics, Inc.(CTNM)

$17.05—Stale · unknown old

Chart

Contineum Therapeutics, Inc.(CTNM)

NASDAQ • Last print unknown ago

$17.05—Stale · unknown old

Chart Studio

CTNM(CTNM)

CTNM

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.45

Oct 29, 2026

Revenue Estimate

$6M

Analyst Sentiment

Wall St. Consensus

Buy

3 analysts·Low coverage

Score

2 Buy (67%)1 Hold (33%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

267%

Hold

133%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$16.00

-6.2%

Consensus

$16.00

-6.2%

Bull

$16.00

-6.2%

12-Month Target Range3 analysts

$16.00$16.00$16.00

Current $17.05Consensus

Current Price

$17.05

Above Consensus

$1.05

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-68.04%

EPS—

FY2028

Rev+56.06%

EPS—

FY2029

Rev+374.52%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$7M	$2M	$3M	$16M	$25M
Low	$7M	$2M	$3M	$16M	$25M
High	$7M	$2M	$3M	$16M	$25M
EBITDA Avg	$-42M	$-48M	$-51M	$-56M	$-64M
Low	$-44M	$-54M	$-51M	$-56M	$-64M
High	$-40M	$-42M	$-51M	$-56M	$-64M
EBIT Avg	$-42M	$-48M	$-51M	$-56M	$-64M
Low	$-44M	$-54M	$-51M	$-56M	$-64M
High	$-40M	$-42M	$-51M	$-56M	$-64M
Net Income Avg	$-42M	$-48M	$-51M	$-57M	$-64M
Low	$-44M	$-54M	$-51M	$-57M	$-64M
High	$-41M	$-42M	$-51M	$-57M	$-64M
EPS Avg	$-1.56	$-1.80	$-1.85	$-2.04	$-2.30
Low	$-1.60	$-1.96	$-1.85	$-2.04	$-2.30
High	$-1.46	$-1.52	$-1.85	$-2.04	$-2.30
Analysts (Rev / EPS)	4 / 5	4 / 5	5 / 2	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$6M	$14M	—	—	—	—	—	—
Low	$6M	$14M	—	—	—	—	—	—
High	$6M	$14M	—	—	—	—	—	—
EBITDA Avg	$-17M	$-11M	—	—	—	—	—	—
Low	$-19M	$-12M	—	—	—	—	—	—
High	$-15M	$-10M	—	—	—	—	—	—
EBIT Avg	$-17M	$-11M	—	—	—	—	—	—
Low	$-19M	$-13M	—	—	—	—	—	—
High	$-15M	$-10M	—	—	—	—	—	—
Net Income Avg	$-17M	$-11M	$-17M	$-18M	$-18M	$-19M	$-12M	$-13M
Low	$-19M	$-13M	$-17M	$-18M	$-18M	$-19M	$-12M	$-13M
High	$-15M	$-10M	$-17M	$-18M	$-18M	$-19M	$-12M	$-13M
EPS Avg	$-0.45	$-0.31	$-0.46	$-0.47	$-0.47	$-0.51	$-0.33	$-0.34
Low	$-0.51	$-0.33	$-0.46	$-0.47	$-0.47	$-0.51	$-0.33	$-0.34
High	$-0.40	$-0.28	$-0.46	$-0.47	$-0.47	$-0.51	$-0.33	$-0.34
Analysts (Rev / EPS)	2 / 5	6 / 5	— / 3	— / 3	— / 3	— / 3	— / 4	— / 4

Earnings Surprises

Recent Analyst Actions

May 14, 2026Morgan Stanley

Contineum price target raised to $16 from $14 at Morgan Stanley

Target:$16.00

+13.1%from $14.15

Jan 8, 2026Morgan Stanley

Contineum downgraded to Equal Weight from Overweight at Morgan Stanley

Target:$14.00

+46.4%from $9.56

Nov 24, 2025Robert W. Baird

Contineum price target lowered to $14 from $16 at Baird

Target:$14.00

+27.9%from $10.95

Nov 21, 2025RBC Capital

Contineum price target lowered to $22 from $25 at RBC Capital

Target:$22.00

+80.0%from $12.22

Sep 25, 2025Leerink Partners

Contineum initiated with an Outperform at Leerink

Target:$20.00

+84.2%from $10.86

Mar 7, 2025Robert W. Baird

Contineum price target lowered to $16 from $32 at Baird

Target:$16.00

+136.3%from $6.77

Oct 21, 2024Robert W. Baird

Baird Starts Contineum Therapeutics (CTNM) at Outperform

Target:$32.00

+99.1%from $16.07

Apr 30, 2024RBC Capital

Contineum initiated with an Outperform at RBC Capital

Target:$30.00

+87.5%from $16.00

Apr 30, 2024Stifel Nicolaus

Stifel Starts Contineum Therapeutics (CTNM) at Buy

Target:$29.00

+81.3%from $16.00

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance